Table 4 Overall response based on prior immunotherapy history in patients who received QL1706 at 5Â mg/kg every 3Â weeks (RP2D)
|  | All patients (n = 468) | Primary tumor type | ||||||
|---|---|---|---|---|---|---|---|---|
NSCLC (n = 121) | NPC (n = 110) | CC (n = 55) | ||||||
Immunotherapy-naive patients (n = 312) | Immunotherapy-treated patients (n = 156) | Immunotherapy-naive patients (n = 66) | Immunotherapy-treated patients (n = 55) | Immunotherapy-naive patients (n = 62) | Immunotherapy-treated patients (n = 48) | Immunotherapy-naive patients (n = 53) | Immunotherapy-treated patients (n = 2) | |
CR, n (%) | 1 (0.3) | 0 | 0 | 0 | 0 | 0 | 1 (1.9) | 0 |
PR, n (%) | 71 (22.8) | 7 (4.5) | 16 (24.2) | 1 (1.8) | 24 (38.7) | 3 (6.3) | 14 (26.4) | 0 |
SD, n (%) | 81 (26.0) | 48 (30.8) | 15 (20.7) | 22 (40.0) | 13 (21.0) | 14 (29.2) | 14 (26.4) | 0 |
PD, n (%) | 133 (42.6) | 80 (51.3) | 32 (48.3) | 20 (36.4) | 24 (38.7) | 28 (58.3) | 16 (30.2) | 2 (100) |
NE, n (%) | 2 (0.6) | 0 | 0 | 0 | 0 | 0 | 1 (1.9) | 0 |
ND, n (%) | 24 (7.7) | 21 (13.5) | 3 (5.2) | 12 (21.8) | 1 (1.6) | 3 (6.3) | 7 (13.2) | 0 |
Confirmed ORR, n (%, 95% CI) | 72 (23.1, 18.5–28.1) | 7 (4.5, 1.8–9.0) | 16 (24.2, 14.5–36.4) | 1 (1.8, 0.04–9.7) | 24 (38.7, 26.6–51.9) | 3 (6.3, 1.3–17.2) | 15 (28.3, 16.8–42.3) | 0 |
DCR, n (%, 95% CI) | 153 (49.0, 43.3–54.7) | 55 (35.3, 27.8–43.3) | 31 (47.0, 34.6–60.0) | 23 (41.8, 28.7–55.9) | 37 (59.7, 46.5–71.9) | 17 (35.4, 22.2–50.5) | 29 (54.7, 40.4–68.4) | 0 |
Number of DoR events (%) | 16 (22.2) | 4 (57.1) | 4 (25.0) | 1 (100) | 7 (29.2) | 2 (66.7) | 2 (13.3) | / |
DoR, m (95% CI) |  − (8.1, –) | 11.7 (4.2, 11.7) |  − (3.5, –) | / |  − (7.7, –) | 11.7 (5.9, 11.7) |  − (–, –) | / |